Concord Biotech has been granted final approval from the United States Food and Drug Administration (USFDA) for marketing its Teriflunomide Tablets, 7 mg and 14 mg. Teriflunomide tablets are used for the treatment of patients with relapsing forms of multiple sclerosis.
This approval reinforces the company’s capability in successfully developing and commercializing a differentiated product portfolio for the U.S. market. According to IQVIA, the market size of Teriflunomide tablets is around $402 million in the US, and the global market size is around $908 million, indicating significant opportunities for expansion in the US and the global market.
Concord Biotech is an India-based biopharma company and one of the leading global developers and manufacturers of select fermentation-based APIs across Immunosuppressants and oncology.
